TY - JOUR
T1 - Symptoms, Physical Activity, and Biomarkers in Children at the End of Leukemia Maintenance Therapy
AU - Hooke, Mary C.
AU - Salisbury, Derek L.
AU - Mathiason, Michelle A.
AU - Kunin-Batson, Alicia S.
AU - Blommer, Audrey
AU - Hutter, Jessica
AU - Mitby, Pauline
AU - Moore, Ida
AU - Whitman, Susan
AU - Taylor, Olga
AU - Scheurer, Michael E.
AU - Hockenberry, Marilyn J.
N1 - Publisher Copyright:
© 2023 by Association of Pediatric Hematology/Oncology Nurses.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background: Symptoms in children with acute lymphocytic leukemia (ALL) change over the trajectory of treatment but little is known about their symptoms as treatment ends. Physical activity may help decrease symptom distress and is vital for ongoing development. The role of biomarkers in symptom science is emerging. The purpose of the study was to explore relationships between self-report of symptoms and physical activity, actigraphy measures, and cerebrospinal fluid (CSF) biomarkers. Methods: Participants were children who were ages 3 to 18 years at the time of ALL diagnosis and were now in the last 12-week cycle of ALL maintenance. Self-reports of fatigue, sleep disturbance, depressive symptoms, and physical activity were completed by participants and parents of younger children. Participants wore a wrist actigraph continuously for the 7 days before other measurements. F2-isoprostanes and interleukin-8 were evaluated in CSF samples. Results: Among the 15 participants, self-report of symptoms and physical activity indicated levels similar to healthy peers. F2-isoprostane had a strong positive correlation with fatigue levels and with depressive symptoms. Fatigue, sleep disturbance, and depressive symptoms positively correlated with each other. Actigraph measures showed children met the CDC guidelines for 60 min of daily moderate to vigorous activity; sleep time was slightly less than healthy norms. Discussion: During maintenance therapy, most children return to healthy norms in symptom burden and physical activity. F2-isoprostane in the CSF is a biomarker for fatigue and depressive symptoms. Children who had persistent symptoms experienced them as a cluster, which confirms previous symptom cluster research.
AB - Background: Symptoms in children with acute lymphocytic leukemia (ALL) change over the trajectory of treatment but little is known about their symptoms as treatment ends. Physical activity may help decrease symptom distress and is vital for ongoing development. The role of biomarkers in symptom science is emerging. The purpose of the study was to explore relationships between self-report of symptoms and physical activity, actigraphy measures, and cerebrospinal fluid (CSF) biomarkers. Methods: Participants were children who were ages 3 to 18 years at the time of ALL diagnosis and were now in the last 12-week cycle of ALL maintenance. Self-reports of fatigue, sleep disturbance, depressive symptoms, and physical activity were completed by participants and parents of younger children. Participants wore a wrist actigraph continuously for the 7 days before other measurements. F2-isoprostanes and interleukin-8 were evaluated in CSF samples. Results: Among the 15 participants, self-report of symptoms and physical activity indicated levels similar to healthy peers. F2-isoprostane had a strong positive correlation with fatigue levels and with depressive symptoms. Fatigue, sleep disturbance, and depressive symptoms positively correlated with each other. Actigraph measures showed children met the CDC guidelines for 60 min of daily moderate to vigorous activity; sleep time was slightly less than healthy norms. Discussion: During maintenance therapy, most children return to healthy norms in symptom burden and physical activity. F2-isoprostane in the CSF is a biomarker for fatigue and depressive symptoms. Children who had persistent symptoms experienced them as a cluster, which confirms previous symptom cluster research.
KW - biomarkers
KW - depressive symptoms
KW - fatigue
KW - leukemia
KW - physical activity
KW - sleep disturbance
UR - http://www.scopus.com/inward/record.url?scp=85153065153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153065153&partnerID=8YFLogxK
U2 - 10.1177/27527530221148479
DO - 10.1177/27527530221148479
M3 - Article
C2 - 37050865
AN - SCOPUS:85153065153
SN - 2752-7530
VL - 40
SP - 386
EP - 399
JO - Journal of Pediatric Hematology/Oncology Nursing
JF - Journal of Pediatric Hematology/Oncology Nursing
IS - 6
ER -